The Cursed Little Black Box of the AI Algorithm

AI-driven drug discovery promises to reveal hitherto mysterious patterns that human researchers miss. Yet a model can produce a confident prediction without making its reasoning easy to inspect, and a strong benchmark result does not guarantee a useful medicine. This is known as the ‘Black Box’ of AI algorithms.

Interpretability in AI drug discovery is therefore central to data quality, reproducibility, scientific decision-making, and trust in the next generation of pharmaceutical research.

Image

Looking Through the Veil

In Drug Discovery, a prediction can look deceptively clear. An AI model ranks a protein as a promising target, estimates how a molecule might bind, or identifies a biological pattern associated with disease.

The output may be precise, visually compelling, and generated in seconds.

But what supports the prediction? Which data shaped it? Would the same model reach the same conclusion with a different dataset, laboratory, or patient population? And does the predicted result correspond to the biological effect that researchers actually need?

These questions sit at the heart of the poisonous black-box problem that has cursed many early AI-driven drug candidates.

Many modern machine-learning systems contain complex relationships between their inputs and outputs.

Even when developers can inspect the model’s architecture, it may be difficult to explain why a particular prediction emerged or which features drove it.

Solving the problem is important because biology is not a fixed, uniform system. Experimental results can change with assay design, cell type, genetic background, environmental conditions, and measurement methods.

A model can learn a pattern in available data without capturing a relationship that remains reliable under different conditions.

This requires that AI drug discovery gets a stronger focus on clinically relevant outcomes, conditional biological data, and the ability of models to improve real research decisions.

There should also be caution against treating numerical progress on benchmarks as proof of translational impact.

The black box is not proof that AI is unreliable. But it is a warning against confusing a model’s output with a scientific explanation, and you may need to look deeper past this Earthly realm to see what’s really happening.

The Spectre of Prediction: Is it All an Illusion?

AI systems can be valuable without reproducing the way a scientist reasons. A model may identify a useful relationship across millions of data points, even when no simple explanation captures the full computation behind its output.

The difficulty arises when researchers need to know what this relationship means.

Imagine a model trained to predict whether a compound will affect a disease-associated protein. It may perform well on a test set because the compounds in that set resemble those used during training.

The model may then struggle when presented with a different chemical series, a new assay, or a protein context that was poorly represented in the original data.

A prediction can also rely on indirect signals.

For example, the model might associate a chemical feature with activity because that feature frequently appears in compounds tested by one laboratory. If the association reflects experimental practice rather than the underlying biology, the system may perform less well when conditions change.

This is why predictive accuracy and biological understanding are not interchangeable. Accuracy measures performance against a defined reference. Understanding requires a defensible account of the relevant mechanism, context, and limitations.

Interpretability techniques can help researchers inspect model behaviour.

Feature attribution, sensitivity analysis, simplified surrogate models, and visualisation tools can indicate which inputs influence an output. However, these methods do not automatically reveal causal mechanisms. A plausible explanation can still be incomplete, unstable, or misleading.

The appropriate question is whether scientists have enough information to assess the prediction, challenge its assumptions, and decide what experiment should follow.

View interview How Should Pharma Companies Audit AI Vendors?

How Should Pharma Companies Audit AI Vendors?

“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."

Image

What Evil Lurks Inside the Black Box?

AI systems inherit the strengths and weaknesses of the data used to build them.

In Drug Discovery, that creates a particularly difficult challenge because biological datasets often combine measurements collected under different experimental conditions and for different purposes.

A dataset may contain results from binding assays, cell-based experiments, animal models, or clinical studies. Although these sources can all contribute useful information, their outputs do not necessarily measure the same thing.

Binding to a target, changing a cellular pathway, and improving a patient outcome are distinct events.

Data quality therefore involves more than removing duplicate records or correcting missing values. Researchers need to understand how a measurement was produced, what it represents, which variables influenced it, and whether it is relevant to the decision the model is intended to support.

A model trained on a technically clean dataset can still learn a weak or misleading relationship if the underlying measurements are poor proxies for the desired outcome.

This issue is particularly important as biological data are conditional and that apparently clean datasets may conceal limitations in their predictivity. Information leakage between training and test data can inflate apparent performance.

This creates a risk of false confidence. Teams may invest in increasingly sophisticated architectures to extract marginal improvements from data that cannot reliably answer the original scientific question.

The priority should instead be to establish whether the data are suitable for the intended use. Sometimes the most valuable investment is not a larger model, but a better experiment, more representative samples, stronger metadata, or a clearer definition of success.

Image

Reproducibility Is the Benchmark Test

A model result becomes more credible when independent researchers can reproduce it or demonstrate that it generalises beyond the conditions in which it was developed.

In AI drug discovery, reproducibility has several layers.

The computational workflow should be documented sufficiently to reconstruct the analysis.

Data sources, processing steps, model versions, and evaluation methods should be traceable. Where possible, independent datasets should test whether the result holds outside the original training environment.

Reproducibility does not mean every laboratory must obtain identical measurements. Biological systems and experiments contain variation. Instead, the goal is to understand that variation, establish which findings are robust, and distinguish a genuine signal from an artefact.

Benchmark design is especially important.

If training and test sets contain closely related compounds, proteins, or experimental records, performance may overstate the model’s ability to handle genuinely new cases.

Prospective testing, in which predictions are evaluated against experiments conducted after the model has been developed, can provide a stronger test of practical value.

The challenge is actually organisational as well as technical.

Experimental scientists, computational researchers, and project leaders may use different definitions of success. A model developer may optimise a metric, while a drug-discovery team needs to know whether the output changes which compound is synthesised, which target is pursued, or which experiment receives funding.

The relevant benchmark should reflect that decision. As a 2019 review in Nature Reviews Drug Discovery also noted, interpretability and repeatability have long been recognised as challenges in applying machine learning across the drug-development pipeline.

It Speaks! What Do Protein Language Models Reveal?

Protein language models illustrate both the opportunity and the limits of interpreting AI predictions.

These systems learn statistical patterns from protein sequences and can support tasks such as predicting properties, representing proteins computationally, and guiding the design or prioritisation of candidate sequences.

Their outputs can help researchers explore biological possibilities that would be difficult to assess manually at scale.

But a sequence that appears promising computationally is not automatically stable, functional, safe, or therapeutically useful.

A model may capture regularities in the proteins represented in its training data while remaining less reliable for unusual sequences, poorly studied protein families, or contexts not reflected in those data.

Researchers still need to test whether a prediction holds under the biological conditions relevant to the intended application.

The distinction is important for any emerging protein-model platform, including systems presented as ways to uncover hidden biological relationships.

The name or sophistication of a model does not establish its scientific validity. Assessment depends on what it was trained to do, how it was evaluated, whether its results can be reproduced, and what independent wet-lab experiments demonstrate.

The same principle applies to generative models that propose new molecules or protein sequences. Generation is a starting point, not proof of function. Experimental confirmation remains necessary to determine whether a designed candidate behaves as predicted.

View interview AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

Image

The Unexplainable?! Explainability Must Match the Decision

Not every AI application requires the same degree of interpretability.

A model used to organise a literature search has a different risk profile from one that influences target selection, compound prioritisation, or a decision to stop a development programme.

Pharma R&D teams should therefore define what they need to understand before choosing an explainability method.

For some applications, they may need to know which variables most influence a prediction. For others, they may need evidence that performance remains stable across laboratories, populations, or experimental conditions.

Where a model supports a high-consequence decision, independent verification, and clear documentation become especially important.

Transparency also needs to reach the people using the system. A model card or technical report can describe intended use, training data, known limitations, and evaluation results.

A concise record of uncertainty can help decision-makers distinguish a robust prediction from one that depends on sparse or indirect evidence.

Regulatory thinking in adjacent areas of health technology reinforces these principles.

The U.S. Food and Drug Administration (FDA), Health Canada, and the UK’s Medicines and Healthcare products Regulatory Agency have published principles for good machine-learning practice, including representative datasets, independent training and test sets, clinically relevant testing, clear information for users, and performance monitoring after deployment.

These principles address medical-device development rather than every drug-discovery model, but they offer a useful framework for risk-based AI governance. 

The objective is to ensure that the level of scrutiny matches the decision being supported.

You Need to Close the Box and Make Sure No One Opens It

R&D teams can reduce black-box risk by making model assessment part of the research workflow, rather than a final check before a result is accepted.

• Define the decision first. Specify the biological or development question, the intended user, and the action the prediction could influence.
• Audit the evidence. Record data provenance, experimental context, missingness, known biases, and the relationship between the measured outcome and the real-world question.
• Test beyond familiar data. Use independent datasets and prospective experiments where feasible. Check for information leakage and avoid relying on a single performance metric.
• Investigate uncertainty. Establish where the model is likely to be less reliable and what additional evidence would change the decision.
• Keep an experimental feedback loop. Compare predictions with laboratory results, investigate discrepancies, and update the model or its intended use when justified.
• Document changes. Preserve model versions, data-processing decisions, evaluation results, and the reasoning behind key research decisions.

These steps need collaboration between data scientists, biologists, medicinal chemists, translational researchers, and quality or governance teams. Without shared definitions and traceable evidence, a technically impressive model can become difficult to evaluate in the context of a real discovery programme.

The principles also connect to broader work on research data management.

The NIH’s overview of FAIR data principles explains how findable, accessible, interoperable, and reusable data can support scientific reuse and reproducibility.

FAIR data do not guarantee biological validity, but they make it easier to inspect how evidence was generated and determine whether it can support a new question.

Image

Trust Is Earned Outside the Black Box

AI can help researchers navigate complex biological systems, prioritise hypotheses, and focus experimental resources.

But a prediction becomes valuable to pharmaceutical R&D only when teams understand what it can support and where its limits lie.

The black box should be treated as a prompt to ask better questions about data, uncertainty, reproducibility, and evidence.

R&D teams who demand prospective testing, transparent documentation, and meaningful biological confirmation will be better positioned to separate genuine discovery opportunities from patterns that fail when tested.

The real breakthrough is not an algorithm that appears to know the answer. It is a research system that makes useful predictions, exposes its limitations, and helps scientists reach decisions they can defend.

At Pharmatica, we believe the future of AI-driven drug discovery depends on more than computational power. It requires the scientific rigour to question predictions, the evidence to reproduce results, and the judgement to distinguish promising hypotheses from meaningful breakthroughs.

By examining the technologies, data, and decisions shaping pharmaceutical innovation, Pharmatica helps industry leaders navigate complexity with greater clarity and confidence.

We know that the race to discover tomorrow’s medicines, progress depends not only on what AI can predict, but on what science can prove.

Sign up to get more Insights.

Pharmatica: Insight. Connection. Impact.